WO2000012677A3 - Generation of recombinant infectious bursal disease viruses by reverse genetics technology and the use of the recombinant viruses as attenuated vaccines - Google Patents
Generation of recombinant infectious bursal disease viruses by reverse genetics technology and the use of the recombinant viruses as attenuated vaccines Download PDFInfo
- Publication number
- WO2000012677A3 WO2000012677A3 PCT/IB1999/001604 IB9901604W WO0012677A3 WO 2000012677 A3 WO2000012677 A3 WO 2000012677A3 IB 9901604 W IB9901604 W IB 9901604W WO 0012677 A3 WO0012677 A3 WO 0012677A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- viruses
- generation
- recombinant
- strains
- attenuated
- Prior art date
Links
- 241000702626 Infectious bursal disease virus Species 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 title abstract 3
- 229940031567 attenuated vaccine Drugs 0.000 title abstract 2
- 230000002238 attenuated effect Effects 0.000 abstract 2
- 238000002741 site-directed mutagenesis Methods 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 229940124590 live attenuated vaccine Drugs 0.000 abstract 1
- 229940023012 live-attenuated vaccine Drugs 0.000 abstract 1
- 230000009456 molecular mechanism Effects 0.000 abstract 1
- 238000002703 mutagenesis Methods 0.000 abstract 1
- 231100000350 mutagenesis Toxicity 0.000 abstract 1
- 230000007918 pathogenicity Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
The invention relates to the generation and mutagenesis of recombinant infectious bursal disease virus by reverse genetics technology. Site-directed mutagenesis of certain amino acid residues on the Non-CEF adapted, very virulent strains of IBDV transforms the viruses into attenuated, CEF-adapted strains. The attenuated, CEF-adapted strains can be used as live vaccines against the very virulent strains. Curently available live attenuated vaccines were generated by serial passage through cell culture and the like, whereas the present invention provides a novel molecular mechanism in manipulation of the viral genome and the generation of attenuated vaccines by site-directed mutagenesis. The same approach can be used to produce vaccine strains from newly evolved IBDV viruses or to manipulate the antigenicity and pathogenicity of the virus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9868498P | 1998-09-01 | 1998-09-01 | |
US60/098,684 | 1998-09-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000012677A2 WO2000012677A2 (en) | 2000-03-09 |
WO2000012677A3 true WO2000012677A3 (en) | 2000-06-29 |
Family
ID=22270458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1999/001604 WO2000012677A2 (en) | 1998-09-01 | 1999-09-01 | Generation of recombinant infectious bursal disease viruses by reverse genetics technology and the use of the recombinant viruses as attenuated vaccines |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2000012677A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1170302B1 (en) * | 2000-07-07 | 2006-06-21 | Intervet International BV | Infectious bursal disease virus vaccines |
US6485940B2 (en) | 2000-07-07 | 2002-11-26 | Akzo Nobel N.V. | Broad spectrum infectious bursal disease virus vaccine |
CN101123871B (en) * | 2003-05-05 | 2011-05-18 | 美国陶氏益农公司 | Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production |
ES2417019T3 (en) * | 2003-11-13 | 2013-08-05 | University Of Georgia Research Foundation, Inc. | Characterization procedure of infectious bursitis disease virus |
CN102258777B (en) * | 2011-06-30 | 2012-09-26 | 河南农业大学禽病研究所 | Method for preparing inactivated vaccine and combined vaccine by breeding infectious bursal disease virus (IBDV) by chicken embryo source cell line |
EP3620505A1 (en) | 2018-09-07 | 2020-03-11 | Henkel AG & Co. KGaA | Mixed metal colloids as bleach boosting agents |
EP3620504A1 (en) | 2018-09-07 | 2020-03-11 | Henkel AG & Co. KGaA | Platinum colloids as bleach boosting agents |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986007060A1 (en) * | 1985-05-30 | 1986-12-04 | Commonwealth Scientific And Industrial Research Or | Cloning and expression of host-protective immunogens of ibdv |
WO1991016925A1 (en) * | 1990-05-04 | 1991-11-14 | University Of Maryland At College Park | Specific dna sequences related to an ibdv protein including vectors, hosts and vaccines |
WO1995026196A1 (en) * | 1994-03-29 | 1995-10-05 | The University Of Maryland College Park | CHIMERIC INFECTIOUS BURSAL DISEASE VIRUS cDNA CLONES, EXPRESSION PRODUCTS AND VACCINES BASED THEREON |
WO1998009646A1 (en) * | 1996-09-05 | 1998-03-12 | University Of Maryland - Biotechnology Institute | A method for generating birnavirus from synthetic rna transcripts |
-
1999
- 1999-09-01 WO PCT/IB1999/001604 patent/WO2000012677A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986007060A1 (en) * | 1985-05-30 | 1986-12-04 | Commonwealth Scientific And Industrial Research Or | Cloning and expression of host-protective immunogens of ibdv |
WO1991016925A1 (en) * | 1990-05-04 | 1991-11-14 | University Of Maryland At College Park | Specific dna sequences related to an ibdv protein including vectors, hosts and vaccines |
WO1995026196A1 (en) * | 1994-03-29 | 1995-10-05 | The University Of Maryland College Park | CHIMERIC INFECTIOUS BURSAL DISEASE VIRUS cDNA CLONES, EXPRESSION PRODUCTS AND VACCINES BASED THEREON |
WO1998009646A1 (en) * | 1996-09-05 | 1998-03-12 | University Of Maryland - Biotechnology Institute | A method for generating birnavirus from synthetic rna transcripts |
Also Published As
Publication number | Publication date |
---|---|
WO2000012677A2 (en) | 2000-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003092592A3 (en) | Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 | |
DE69842165D1 (en) | PREPARATION OF ATTENUATED PARAIN FLUENZA VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES | |
CA2366072A1 (en) | Prrsv vaccines | |
DE69737886D1 (en) | INFECTIOUSE RNA VIRUS CLONE, VACCINE, AND THEREFORE DERIVED DIAGNOSTIC ASSAYS | |
DK0550553T3 (en) | Viral defective vaccine made from a trans-complementing cell line | |
DE69830579D1 (en) | CHIMERIC VACCINES AGAINST FLAVIVIRES | |
CA2370372A1 (en) | Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142 | |
CN110904153A (en) | Construction method and application of recombinant porcine reproductive and respiratory syndrome virus for expressing African swine fever virus p12 or p17 protein | |
WO2000012677A3 (en) | Generation of recombinant infectious bursal disease viruses by reverse genetics technology and the use of the recombinant viruses as attenuated vaccines | |
WO2003023040A3 (en) | Vaccinia virus mva-e3l-knockout-mutants and use thereof | |
BR0012433A (en) | Recombinant virus, infectious from infectious bursal disease, method to obtain the same, ibdv infectious mosaic (mibdv), and vaccine | |
UA84667C2 (en) | Vaccine directed against infection induced by herpes virus of marek's disease | |
DE69533067D1 (en) | HEPATIS E-VIRUS ANTIGENE AND THEIR USE | |
WO1994000586A3 (en) | Infectious bovine rhinotracheitis virus mutants and vaccines | |
MXPA01005808A (en) | Ibdv strain for in ovo administration. | |
ATE494377T1 (en) | VACCINES AGAINST IPNV THAT ARE ISOLATED FROM Yeast CELLS | |
WO1995003399A3 (en) | Production method for preparation of disabled viruses | |
EP1427443A4 (en) | Vaccine using papilloma virus e proteins delivered by viral vector | |
CA2363493A1 (en) | Attenuated forms of bovine viral diarrhea virus | |
WO1999057284A3 (en) | Attenuated influenza viruses | |
WO1996001615A3 (en) | Hepatitis a virus deletion mutants and vaccine formulations containing the same | |
ATE342731T1 (en) | VIRUS VACCINE CHARACTERIZED BY A BHV-1 GENE ELETION | |
WO2005000881A3 (en) | Live attenuated viral vaccines for eastern equine encephalitis virus | |
CA2495294A1 (en) | Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines | |
WO2001049712A3 (en) | Vaccine against isav (infectious salmon anaemia virus) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
122 | Ep: pct application non-entry in european phase |